CARDIOGRAFIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIOGRAFIN is an injectable diagnostic contrast agent used in cardiac imaging procedures, likely a iodinated contrast medium for angiography or other cardiovascular visualization. The product mechanism enables radiographic visualization of cardiac and coronary structures via X-ray imaging.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), likely a contracting franchise facing generic/biosimilar competition with reduced team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CARDIOGRAFIN offers limited career growth potential as a legacy diagnostic product at LOE with minimal active job openings (0 linked positions). Working on this asset involves defensive brand management, margin protection, and eventual transition planning rather than expansion or innovation.
Brand ManagerProduct Manager
Worked on CARDIOGRAFIN at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.